Sökning: WFRF:(Cruz M. Waddington)
> (2012) >
Tafamidis for trans...
Tafamidis for transthyretin familial amyloid polyneuropathy : A randomized, controlled trial
-
Coelho, Teresa (författare)
-
Maia, Luis F. (författare)
-
da Silva, Ana Martins (författare)
-
visa fler...
-
Cruz, Marcia Waddington (författare)
-
Plante-Bordeneuve, Violaine (författare)
-
Lozeron, Pierre (författare)
-
- Suhr, Ole B. (författare)
- Umeå universitet,Medicin
-
Campistol, Josep M. (författare)
-
Conceicao, Isabel Maria (författare)
-
Schmidt, Hartmut H. -J. (författare)
-
Trigo, Pedro (författare)
-
Kelly, Jeffery W. (författare)
-
Labaudinie, Richard (författare)
-
Chan, Jason (författare)
-
Packman, Jeff (författare)
-
Wilson, Amy (författare)
-
Grogan, Donna R. (författare)
-
visa färre...
-
(creator_code:org_t)
- Philadelphia : Lippincott Williams & Wilkins, 2012
- 2012
- Engelska.
-
Ingår i: Neurology. - Philadelphia : Lippincott Williams & Wilkins. - 0028-3878 .- 1526-632X. ; 79:8, s. 785-792
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objectives: To evaluate the efficacy and safety of 18 months of tafamidis treatment in patients with early-stage V30M transthyretin familial amyloid polyneuropathy (TTR-FAP). Methods: In this randomized, double-blind trial, patients received tafamidis 20 mg QD or placebo. Coprimary endpoints were the Neuropathy Impairment Score-Lower Limbs (NIS-LL) responder analysis (<2-point worsening) and treatment-group difference in the mean change from baseline in Norfolk Quality of Life-Diabetic Neuropathy total score (TQOL) in the intent-to-treat (ITT) population (n = 125). These endpoints were also evaluated in the efficacy-evaluable (EE; n = 87) population. Secondary endpoints, including changes in neurologic function, nutritional status, and TTR stabilization, were analyzed in the ITT population. Results: There was a higher-than-anticipated liver transplantation dropout rate. No differences were observed between the tafamidis and placebo groups for the coprimary endpoints, NIS-LL responder analysis (45.3% vs 29.5% responders; p = 0.068) and change in TQOL (2.0 vs 7.2; p = 0.116) in the ITT population. In the EE population, significantly more tafamidis patients than placebo patients were NIS-LL responders (60.0% vs 38.1%; p = 0.041), and tafamidis patients had better-preserved TQOL (0.1 vs 8.9; p = 0.045). Significant differences in most secondary endpoints favored tafamidis. TTR was stabilized in 98% of tafamidis and 0% of placebo patients (p < 0.0001). Adverse events were similar between groups. Conclusions: Although the coprimary endpoints were not met in the ITT population, tafamidis was associated with no trend toward more NIS-LL responders and a significant reduction in worsening of most neurologic variables, supporting the hypothesis that preventing TTR dissociation can delay peripheral neurologic impairment. Classification of evidence: This study provides Class II evidence that 20 mg tafamidis QD was associated with no difference in clinical progression in patients with TTR-FAP, as measured by the NIS-LL and the Norfolk QOL-DN score. Secondary outcomes demonstrated a significant delay in peripheral neurologic impairment with tafamidis, which was well tolerated over 18 months. Neurology (R) 2012;79:785-792
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Coelho, Teresa
-
Maia, Luis F.
-
da Silva, Ana Ma ...
-
Cruz, Marcia Wad ...
-
Plante-Bordeneuv ...
-
Lozeron, Pierre
-
visa fler...
-
Suhr, Ole B.
-
Campistol, Josep ...
-
Conceicao, Isabe ...
-
Schmidt, Hartmut ...
-
Trigo, Pedro
-
Kelly, Jeffery W ...
-
Labaudinie, Rich ...
-
Chan, Jason
-
Packman, Jeff
-
Wilson, Amy
-
Grogan, Donna R.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Neurology
- Av lärosätet
-
Umeå universitet